InterMune撤资减少actimune®专注于Esbriet®

Pharmadeals Review Pub Date : 2012-05-28 DOI:10.3833/pdr.v2012i5.1746

Heather Cartwright

{"title":"InterMune撤资减少actimune®专注于Esbriet®","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1746","DOIUrl":null,"url":null,"abstract":"InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"InterMune Divests Declining Actimmune® to Focus on Esbriet®\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2012i5.1746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2012i5.1746\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2012i5.1746","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

InterMune已同意将Actimmune®(干扰素γ -1b)的权利出售给Vidara Therapeutics International，价格为5500万美元现金加上两年的版税。Actimmune®被批准用于治疗慢性肉芽肿疾病和严重恶性骨质硬化。此次交易的收益将帮助InterMune投资其特发性肺纤维化药物Esbriet®(吡非尼酮)在欧洲和其他地区的注册和商业化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

InterMune Divests Declining Actimmune® to Focus on Esbriet®

InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量